Evidence map›Paper›PMID 40592719›Full record

SynthesisBritish journal of clinical pharmacology2025

Electronic medicine management systems in developing countries: A landscape review.

Andrew Lambarth, Dalia Wainwright, Trisha Saha, Millicent Banks, Iona Minty, P A M K Abeywickrama, Reya V Shah, Yogini Jani, Reecha Sofat

Abstract readSystematic Review
In one paragraph

Synthesis in British journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andrew LambarthDepartment of Clinical Pharmacology and Therapeutics, City St George's, University of London, London, UK.ORCID https://orcid.org/0000-0003-2625-6867
Dalia WainwrightOxford University Hospitals NHS Foundation Trust, Oxford, UK.
Trisha SahaSchool of Medicine, University College London, London, UK.
Millicent BanksUniversity Hospital Southampton NHS Foundation Trust, Southampton, UK.
Iona MintyDepartment of Infectious Diseases, University College Hospital, London, UK.
P A M K AbeywickramaDepartment of Clinical Pharmacology and Therapeutics, City St George's, University of London, London, UK.
Reya V ShahDepartment of Clinical Pharmacology and Therapeutics, City St George's, University of London, London, UK.
Yogini JaniSchool of Pharmacy, University College London, London, UK.
Reecha SofatBHF Data Science Centre, HDRUK, London, UK.ORCID https://orcid.org/0000-0002-0242-6115

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medicines are a major global health expense. However, suboptimal use increases costs and causes patient harm. One way to reduce costs and increase safe, efficient medicines use is with electronic medicines management systems (EMMS). They allow easy capture of routine health data which can facilitate research, service planning and reimbursement processes. There are various barriers to healthcare digitization in developing countries (DCs), although some have overcome these. We sought to understand the landscape of EMMS use in DCs. We systematically searched six bibliographic databases from inception to 23 October 2024 for studies reporting the implementation and/or use of EMMS in countries with lower than 'very high' Human Development Index (HDI). We qualitatively and quantitatively summarized data on geographic location, healthcare setting and system functionality. We created an interactive map illustrating spatial and temporal trends in EMMS use. A total of 314 records described the use of EMMS in 45 DCs, 206 of which described coexistence/integration of other health data (e.g., electronic health records [EHR]). Predominantly, EMMS were for prescribing (n = 264) or dispensing (n = 66), implemented in secondary care settings and operated locally rather than regionally or nationally. Common EMMS use-cases included adherence monitoring in human immunodeficiency virus (HIV) and tuberculosis treatment. Our findings highlight both widespread EMMS adoption-commonly in the context of a broader EHR-and persistent gaps in implementation. These insights could be used by policymakers and healthcare leaders to guide strategy and funding decisions. Existing systems could be leveraged for service planning, healthcare delivery and optimizing medicine use. Where EMMS are not yet in use, our findings provide a roadmap for stakeholders to identify and emulate successful implementations in similar healthcare settings. Expanding the interoperability and scale of EMMS could further enable transformative digital technologies, increasing efficiencies and coverage, and ultimately improving patient outcomes.

Indexed as

Developing CountriesElectronic Health RecordsDelivery of Health CareHumansdeveloping countriesdigitalelectroniclow‐ and middle‐income countriesmedicine managementreview

Identifiers

PMID40592719
PMCPMC12381608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.